ArriVent BioPharma (AVBP) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 278.1% versus a loss of 12.5%. ArriVent BioPharma is the larger company by market cap ($832.8 million vs $786.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | IMMX |
|---|---|---|
| Share price | $16.89 | $9.49 |
| Market cap | $832.81M | $786.75M |
| 1-day change | +11.93% | -1.56% |
| YTD return | -16.05% | +81.45% |
| 1-year return | -12.53% | +278.09% |
| EPS (TTM) | $-4.05 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $15.10 |
| 52-week low | $11.36 | $2.31 |
| Distance from 52-week high | -52.86% | -37.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.58% | +156.06% |
| Average volume | 826.82K | 1.66M |
| Shares outstanding | 49.31M | 82.90M |
| Employees | 77 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed AVBP by 290.6 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Healthcare · Biotechnology · 77 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Healthcare · Biotechnology · 21 employees
AVBP vs IMMX FAQ
Which is bigger, ArriVent BioPharma or Immix Biopharma?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $832.81M compared with $786.75M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, AVBP or IMMX?
IMMX returned +278.09% over the past 12 months, compared with -12.53% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.